



## OPEN ACCESS

EDITED AND REVIEWED BY  
Catherine Sautes-Fridman,  
INSERM U1138 Centre de Recherche  
des Cordeliers (CRC), France

## \*CORRESPONDENCE

Manel Juan  
mjjuan@clinic.cat

## SPECIALTY SECTION

This article was submitted to  
Cancer Immunity  
and Immunotherapy,  
a section of the journal  
Frontiers in Immunology

RECEIVED 23 October 2022

ACCEPTED 09 November 2022

PUBLISHED 21 November 2022

## CITATION

Ramírez-Chacón A, Betriu-Méndez S,  
Bartoló-Ibars A, González A, Martí M  
and Juan M (2022) Corrigendum:  
Ligand-based CAR T-cell: Different  
strategies to drive T-cells in future  
new treatments.  
*Front. Immunol.* 13:1078003.  
doi: 10.3389/fimmu.2022.1078003

## COPYRIGHT

© 2022 Ramírez-Chacón,  
Betriu-Méndez, Bartoló-Ibars, González,  
Martí and Juan. This is an open-access  
article distributed under the terms of  
the [Creative Commons Attribution  
License \(CC BY\)](#). The use, distribution  
or reproduction in other forums is  
permitted, provided the original  
author(s) and the copyright owner(s)  
are credited and that the original  
publication in this journal is cited, in  
accordance with accepted academic  
practice. No use, distribution or  
reproduction is permitted which does  
not comply with these terms.

# Corrigendum: Ligand- based CAR T-cell: Different strategies to drive T-cells in future new treatments

Alejandro Ramírez-Chacón<sup>1,2</sup>, Sergi Betriu-Méndez<sup>3,4</sup>,  
Ariadna Bartoló-Ibars<sup>3,4</sup>, Azucena González<sup>3,4,5</sup>, Mercè Martí<sup>1,2</sup>  
and Manel Juan<sup>3,4,5\*</sup>

<sup>1</sup>Immunology Unit, Department of Cellular Biology, Physiology and Immunology, Universitat Autònoma de Barcelona (UAB), Cerdanyola del Vallès, Spain, <sup>2</sup>Laboratory of Cellular Immunology, Institute of Biotechnology and Biomedicine (IBB), Cerdanyola del Vallès, Spain, <sup>3</sup>Immunology Department, Hospital Clínic de Barcelona, Centre de Diagnòstic Biomèdic (CDB), Barcelona, Spain, <sup>4</sup>Immunology Department, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) –Fundació Clínic per a la Recerca Biomèdica (FCRB) Universitat de Barcelona (UB), Barcelona, Spain, <sup>5</sup>Immunology Department, Hospital Sant Joan de Déu, Barcelona, Spain

## KEYWORDS

T cells, chimeric antigen receptor (CAR), ligands, receptor, antigen, CAAR, BAR

## A corrigendum on

**Ligand-based CAR-T cell: Different strategies to drive T cells in future new treatments**

by Ramírez-Chacón A, Betriu-Méndez S, Bartoló-Ibars A, González A, Martí M and Juan M (2022) *Front. Immunol.* 13:932559. doi: 10.3389/fimmu.2022.932559

In the published article, there was an error in the Funding statement. Missing grant supporting this manuscript. The correct Funding statement appears below.

**Funding**

“Thanks to Immunology department (Hospital Clínic de Barcelona) and Institute of Biotechnology and Biomedicine (IBB-UAB) for their help during the writing of this article. This work has been partially supported by grants from the Instituto de Salud Carlos III, Spanish Ministry of Health (FIS PI18/00775, PIC118/00012 and complementary grant for CONCORD-023), Fondo Europeo de Desarrollo Regional (FEDER) “una manera de hacer Europa”, “La Caixa” Foundation (CP042702/LCF/PR/GN18/50310007), and Secretaria d'Universitats i Recerca del Departament d'Empresa i Coneixement, Generalitat de Catalunya, project 2020PANDE00079.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.